从1999年到2018年，瑞典甲状腺癌的生存
Survival in Thyroid Cancer in Sweden From 1999 To 2018
影响因子:3.20000
分区:医学3区 / 公共卫生2区
发表日期:2024
作者:
Frantisek Zitricky, Anni Koskinen, Kristina Sundquist, Jan Sundquist, Vaclav Liska, Asta Försti, Akseli Hemminki, Kari Hemminki
摘要
甲状腺癌（TC）在几种组织学类型中被诊断出，其临床特征和存活率有所不同。我们的目的是描述它们如何影响瑞典的TC存活。从1999年至2018年之间，从瑞典癌症注册中获得了癌症数据，这些数据用于分析相对生存。当在10年内分析的所有TC的递变生存率都在10年内改善，而女性存活率提高了，而女性的生存率提高了。对于特定的组织学类型，女性生存优势似乎也存在，尽管稀有类型的病例数很低。卵泡的女性5年相对生存率为100％，肿瘤细胞为95.1％，乳头状为93.4％，髓质为89.7％，而对变性癌为6.1％。在临床TNM类别中，与T1-3和M0相比，仅T4和M1阶段与生存降低有关。与其他TC相比，那种肿瘤癌最常见于高T和M1阶段。奇怪的是，对变性M1患者的诊断年龄低于M0患者的诊断年龄。与主要的组织学类型相比，变性和髓质癌的转移概率都没有显示出年龄依赖性的增加。这可能表明存在几种类型的那内肿瘤和髓质癌。对变性TC的生存率较差与分化TC的出色生存形成鲜明对比。由于不到20％的变性癌症患者幸存了一年，因此紧急诊断和治疗开始很重要。在丹麦建立了促进的治疗途径，从而提高了生存率。主体癌应成为主要研究重点的目标。
Abstract
Thyroid cancer (TC) is diagnosed in several histological types which differ in their clinical characteristics and survival. We aim to describe how they influence TC survival in Sweden.Cancer data were obtained from the Swedish cancer registry between years 1999 and 2018, and these were used to analyze relative survival.Relative survival for all TC improved when analyzed in 10-year periods, and female survival improved more than male survival. Female survival advantage appeared to be present also for specific histological types, although case numbers were low for rare types. Female 5-year relative survival for TC was 100% for follicular, 95.1% for oncocytic, 93.4% for papillary, 89.7% for medullary, and 6.1% for anaplastic cancer. Among the clinical TNM classes, only T4 and M1 stages were associated with decreased survival compared to T1-3 and M0. Anaplastic cancer presented most often at high T and M1 stages, in contrast to other TC. Curiously, the diagnostic age for anaplastic M1 patients was lower than that for M0 patients. Both anaplastic and medullary cancers did not show age-dependent increases in the probability of metastases, in contrast to the main histological types. This could indicate the presence of several types of anaplastic and medullary cancers.The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research focus.